Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19
Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19
复制标题
DOI：
10.12788/jhm.3497
复制
发表时间：
2020-08-01
影响因子：
2.6
通讯作者：
Southern, William
中科院分区：
文献类型：
--
作者：
Keller, Marla J.;Kitsis, Elizabeth A.;Southern, William
糖皮质激素在COVID-19中的疗效尚不清楚。这项研究旨在确定COVID-19患者的全身糖皮质激素治疗是否与死亡率降低或机械通气相关。这项观察性研究包括1，806名住院的COVID-19患者; 140名患者在入院后48小时内接受了糖皮质激素治疗。早期使用糖皮质激素与死亡率或机械通气无关。然而，初始C反应蛋白（CRP）>= 20 mg/dL的患者接受糖皮质激素治疗与死亡或机械通气风险显著降低相关（比值比，0.23; 95% CI，0.08-0.70），而CRP>= 20 mg/dL的患者接受糖皮质激素治疗与死亡或机械通气风险显著降低相关（比值比，0.23; 95% CI，0.08-0.70），
The efficacy of glucocorticoids in COVID-19 is unclear. This study was designed to determine whether systemic glucocorticoid treatment in COVID-19 patients is associated with reduced mortality or mechanical ventilation. This observational study included 1,806 hospitalized COVID-19 patients; 140 were treated with glucocorticoids within 48 hours of admission. Early use of glucocorticoids was not associated with mortality or mechanical ventilation. However, glucocorticoid treatment of patients with initial C-reactive protein (CRP) >= 20 mg/dL was associated with significantly reduced risk of mortality or mechanical ventilation (odds ratio, 0.23; 95% CI, 0.08-0.70), while glucocorticoid treatment of patients with CRP